Skip to main content
Retour
Watch Compare

Entera Bio Ltd.

Qualité des données : 83%
Également cotée sous ENTX Nasdaq
ENTXW
Nasdaq Manufacturing Chemicals

Quick Summary

Points Clés

Revenue declined -47,92% annually over 5 years
Negative free cash flow of -7,48 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 28,88%
Capital intensive — 254,76% of revenue goes to capex

Croissance

Revenue Growth (5Y)
-47,92%
En dessous de la moyenne du secteur (9,35%)
Revenue (1Y)-76,80%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-70,42%
En dessous de la moyenne du secteur (-51,02%)
ROIC-54,12%
Net Margin-27235,71%
Op. Margin-27450,00%

Sécurité

Debt / Equity
N/A
Current Ratio10,83
Interest CoverageN/A

Valorisation

P/E Ratio
N/A
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (44 pairs)
Métrique Action Médiane du Secteur
P/E — -2,0
P/B — 5,1
ROE % -70,4 -51,0
Net Margin % -27235,7 -150,2
Rev Growth 5Y % -47,9 9,3
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -76,80% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -47,92% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 42 000,0 Net Income (TTM) -11,44 M
ROE -70,42% ROA -61,71%
Gross Margin 0,00% Operating Margin -27450,00%
Net Margin -27235,71% Free Cash Flow (TTM) -7,48 M
ROIC -54,12% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 10,83
Interest Coverage N/A Asset Turnover 0,00
Working Capital 15,44 M Tangible Book Value 15,23 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio N/A Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield N/A
Market Cap N/A Enterprise Value N/A
Per Share
EPS (Diluted TTM) 0,25 Revenue / Share N/A
FCF / Share N/A OCF / Share N/A
EPS CAGR (1Y) 0,00% EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 254,76% FCF Conversion 65,36%
SBC-Adj. FCF -10,45 M Growth Momentum -28,88

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 42 000,0 181 000,0 0,0 134 000,0 571 000,0
Net Income -11,44 M -9,54 M -8,89 M -13,07 M -12,19 M
EPS (Diluted) 0,25 0,25 0,31 0,45 —
Gross Profit 0,0 9 000,0 0,0 33 000,0 198 000,0
Operating Income -11,53 M -9,59 M -8,89 M -13,02 M -12,22 M
EBITDA — — — — —
R&D Expenses 6,00 M 4,50 M 4,51 M 5,85 M 6,77 M
SG&A Expenses 398 000,0 — — — —
D&A — — — — —
Interest Expense — — — — —
Income Tax 0,0 14 000,0 29 000,0 137 000,0 -59 000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 15,99 M 9,39 M 11,77 M 13,13 M 25,99 M
Total Liabilities 2,89 M 1,31 M 1,38 M 1,37 M 3,42 M
Shareholders' Equity 13,10 M 8,08 M 10,39 M 11,75 M 22,57 M
Total Debt — — — — —
Cash & Equivalents 7,11 M 8,66 M 11,02 M 12,31 M 24,89 M
Current Assets 15,30 M 8,97 M 11,26 M 12,85 M 25,33 M
Current Liabilities 2,20 M 1,18 M 1,09 M 1,34 M 3,16 M